Basic Information
| LncRNA/CircRNA Name | LEF1-AS1 |
| Synonyms | LEF1-AS1, LEF1NAT |
| Region | GRCh38_4:108167525-108256836 |
| Ensemble | ENSG00000232021 |
| Refseq | NR_029373 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioblastoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot |
| Sample | celll ines (Human 293FT cells and U251 and U87 glioma cells) |
| Expression Pattern | up-regulated |
| Function Description | Here, for the first time, the effects of lncRNA lymphoid enhancer-binding factor 1 antisense RNA 1 (LEF1-AS1) on GBM progression both in vitro and in vivo are investigated.Finally, the in vivo experiment also demonstrated that knockdown LEF1-AS1 inhibited the growth-promoting effect of LEF1-AS1 of U87 cells.Several publications have recently provided compelling evidence that the expression patterns of lncRNAs were of vast importance associated with the pathogenesis of malignant tumors, including tumorigenesis, drug resistance, and metastasis.The Kaplan-Meier analysis and the log-rank test indicated that the 5-year overall survival in GBM patients with high expression of LEF1-AS1 was notably shorter than that with low expression (P<0.0001) (Figure 1B). |
| Pubmed ID | 28894380 |
| Year | 2017 |
| Title | LEF1-AS1, a long-noncoding RNA, promotes malignancy in glioblastoma. |
External Links
| Links for LEF1-AS1 | GenBank HGNC NONCODE |
| Links for glioblastoma | OMIM COSMIC |